News / Canada / bnn_bloomberg
Aurora Cannabis Advises Investors to Reject Unsolicited Curaleaf Takeover Bid
Health Technology · Biotechnology · bnn_bloomberg · 2026-09-02
Aurora Cannabis is formally recommending that shareholders decline a hostile acquisition offer from Curaleaf, citing significant undervaluation.
What Happened
Board Recommendation: Aurora Cannabis has officially urged its shareholders to reject the unsolicited takeover attempt initiated by Curaleaf Holdings. The company's leadership maintains that the current offer fails to reflect the true value of the business and does not serve the long-term interests of its investors.
Financial Standing: Aurora highlights its strong balance sheet, noting that it is currently debt-free with approximately C$149 million in cash reserves. In contrast, the company points out that Curaleaf carries over C$1 billion in debt, suggesting the bid is a strategic move to access Aurora's liquidity.
Strategic Concerns: CEO Miguel Martin expressed concerns that Curaleaf is attempting to leverage Aurora's own cash to finance the acquisition. He argued that the proposal would allow the bidder to acquire assets at a steep discount while transferring substantial financial risks onto Aurora's existing shareholder base.
Bid Details: The offer, made last month, is valued at roughly US$4.00 per share, consisting of a mix of Curaleaf stock and cash. Aurora shares closed at C$5.60 on the Toronto Stock Exchange following the announcement, as the market continues to monitor the potential impact of this hostile maneuver.